CD24: A Novel Target for Cancer Immunotherapy

Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor CD24 expression has been linked with alterations in several oncogenic signaling pathways. In addition, the CD24/Siglec-10 interaction has been implicated in tumor immune evasion, inhibiting macrophagemediated phagocytosis as well as natural killer (NK) cell cytotoxicity. CD24 blockade has shown promising results in preclinical studies. Although there are limited data on efficacy, monoclonal antibodies against CD24 have demonstrated clinical safety and tolerability in two clinical trials. Other treatment modalities evaluated in the preclinical setting include antibody-drug conjugates and chimeric antigen receptor (CAR) T cell therapy. In this review, we summarize current evidence and future perspectives on CD24 as a potential target for cancer immunotherapy.

Automated summary

Cluster of differentiation 24 (CD24) is a cell adhesion protein that is expressed by various cell types and has been linked to oncogenic signaling pathways and tumor immune evasion. CD24 blockade has shown promising results in preclinical studies, and monoclonal antibodies against CD24 have demonstrated clinical safety and tolerability in clinical trials. CD24 may serve as a potential target for cancer immunotherapy.